19.08 USD
▼+0.19-0.83%
盘后 19.24 0.00%
2026-08-03
市值
$1.69B
市盈率
—
EPS
-2.79
股息率
—
52 周区间
9.68 – 25.59
成交量
2.04M
Beta
0.37
目标价
39.45
52W 低 9.6852W 高 25.59
价格走势
公司简介
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination...